Adolescent Medicine

Alcohol Abuse

Allergies and Infant Formula

Allergy, Immunology, and ENT

Animal Allergies

Autism

COVID-19

Cardiovascular Diseases

Cardiology

Atopic Dermatitis

Acne

Dermatology

Developmental/Behavioral Disorders

Drug Pipeline News

Emergency Medicine

Diabetes

Diabetes Type 2

Endocrinology

Gastroenterology

Gynecology

Antibiotic Resistance

Vaccination and Immunization

Bacterial Conjunctivitis

Vaccines

Infectious disease

Influenza

Anxiety

Depression

Mental Health

Concussion

Epilepsy

Headache

Neurology

Food Allergies

Obesity

Childhood Obesity

Nutrition

Nutrition News

Neonatal/Perinatology

Obstetrics-Gynecology & Women's Health

Oncology

Pain

Pharmacology

Practice Improvement

ADHD

Antisocial Personality Disorder

Psychiatry

Asthma

Cystic Fibrosis

Pediatric Asthma

Pneumonia

Respiratory

Rheumatoid Arthritis

Sexually Transmitted Diseases

Sexual Health

Skin Diseases

Telemedicine

News 

All News

PNP Corner

AAP Guidelines

Media

Around the Practice

Cure Connections

Expert Interviews

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Podcasts

Webinars

Puzzler

Publications

Contemporary Pediatrics Journal

Supplements And Featured Publications

CME/CE

Resources

Handouts

Job Board

Conferences

Conference Coverage

Conference Listing

Partnerships

Subscribe

Print Subscription

eNewsletter

Editorial

Editorial Advisory Board

Writer’s Guidelines

Reference Guidelines

Meet the Editors

Articles

In a recent study, increased rates of precocious puberty were observed during the COVID-19 pandemic compared to prior years.

Early puberty rates increased during the COVID-19 pandemic

Joshua Fitch is an editor for Contemporary Pediatrics. 

In this Contemporary Pediatrics interview, James Wallace, MD, discusses increased trends in school avoidance and the negative effects associated with less days in the classroom. 

School avoidance trends and the negative effects associated with excessive missed days

Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older. 

Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up

Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years. 

Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis 

About Us

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Contemporary Pediatrics

Facebook

Twitter

LinkedIn

Instagram

Spotlight

2022 Best Tech

Changing Landscape in RSV Prevention

Food Insecurity and the Dangers of Infant Formula Dilution

Getting into the Roots of Childhood Atopic Dermatitis

Opt-Out Chlamydia Screening in Adolescent Care

The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants

Update in Pediatric COVID-19 Vaccines

Clinical

View More

1rem

Authors

Better technology is good for patient health and the financial health of physicians’ practices.

Reduce patient no-shows with a personalized, digital solution-driven approach

Braden Neish, MBA

Articles